The transwell chamber assay clearly revealed that CC cells treatment with 100 ng/ml and 200 ng/ml recombinant human CCL22 could increase the migration ability and neutralization with the CCL22 antibody reversed CCR4-expressing CC cell migration augment (Fig. 4A), indicating that CCL22 secreted by cervical cancer cells bound with CCR4 which expressed on the surface of cancer cells could promote CC cells migration, we assessed the effect of CCL22 bound with CCR4 on a few essential EMT markers, vimentin, Zona Occludens 1 (ZO-1) and slug, snail and β-catenin. This evidence concerns the gene CCR4 and cervical cancer.